Pda Technical Report 82 |best| -

The PDA first published Technical Report 82 in 2015, with the aim of providing a detailed framework for evaluating sterile compounding facilities. The report was developed by a team of experts with extensive experience in sterile compounding, facility design, and regulatory compliance. TR 82 provides guidance on the key elements of sterile compounding facilities, including design, construction, and operation.

When filing a New Drug Application (NDA) or Biologics License Application (BLA), compliance teams should leverage PDA TR 82 to build a robust, science-based justification for their endotoxin control strategy. Failing to address LER adequately can result in significant regulatory delays, Complete Response Letters (CRLs), or requests for extensive re-validation. Conclusion pda technical report 82

: LER studies are often a requirement for Biological License Applications (BLA). Industry Impact and Updates The PDA first published Technical Report 82 in

If a product is found to be susceptible to LER during hold-time studies, PDA TR 82 offers several approaches to mitigate the problem: When filing a New Drug Application (NDA) or

By the mid-2010s, the FDA began formally requesting LER-type hold-time studies as a requirement for Biologics License Applications (BLAs), particularly for products with formulations prone to endotoxin masking. In BLA review letters, the FDA has explicitly required sponsors to "evaluate the effect of hold time on endotoxin detection by spiking a known amount of standard endotoxin into undiluted DP and test for recoverable endotoxin over time".